芳香酶抑制剂治疗绝经后乳腺癌患者的骨修饰剂:超越骨保护?

Breast disease Pub Date : 2023-01-01 DOI:10.3233/BD-220014

Andrea Villasco, Carola Minella, Valentina Elisabetta Bounous, Roberta Rosso, Nicoletta Biglia

{"title":"芳香酶抑制剂治疗绝经后乳腺癌患者的骨修饰剂:超越骨保护?","authors":"Andrea Villasco, Carola Minella, Valentina Elisabetta Bounous, Roberta Rosso, Nicoletta Biglia","doi":"10.3233/BD-220014","DOIUrl":null,"url":null,"abstract":"Estrogen-receptor positive tumours represent the majority of breast cancers in postmenopausal women. Adjuvant endocrine therapy with aromatase inhibitors (AIs), continued for up to 10 years in high-risk patients, reduces by 40% the risk of recurrence. However, this therapy, among other side effects, is burdened with a higher incidence of osteoporotic bone fractures. To date, both bisphosphonates and denosumab are recognized as first-line drugs in the primary prevention of osteoporotic fractures in patients treated with AIs. They have demonstrated their effectiveness in increasing bone mineral density and in reducing the incidence of fractures, but they have also been shown to improve disease free survival (DFS).","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bone modifying agents in postmenopausal breast cancer patients treated with aromatase inhibitors: beyond bone protection?\",\"authors\":\"Andrea Villasco, Carola Minella, Valentina Elisabetta Bounous, Roberta Rosso, Nicoletta Biglia\",\"doi\":\"10.3233/BD-220014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Estrogen-receptor positive tumours represent the majority of breast cancers in postmenopausal women. Adjuvant endocrine therapy with aromatase inhibitors (AIs), continued for up to 10 years in high-risk patients, reduces by 40% the risk of recurrence. However, this therapy, among other side effects, is burdened with a higher incidence of osteoporotic bone fractures. To date, both bisphosphonates and denosumab are recognized as first-line drugs in the primary prevention of osteoporotic fractures in patients treated with AIs. They have demonstrated their effectiveness in increasing bone mineral density and in reducing the incidence of fractures, but they have also been shown to improve disease free survival (DFS).\",\"PeriodicalId\":9224,\"journal\":{\"name\":\"Breast disease\",\"volume\":\"42 1\",\"pages\":\"1-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/BD-220014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-220014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

雌激素受体阳性肿瘤占绝经后妇女乳腺癌的大多数。在高危患者中使用芳香酶抑制剂(AIs)进行辅助内分泌治疗长达10年，可减少40%的复发风险。然而，除其他副作用外，这种疗法还具有较高的骨质疏松性骨折发生率。迄今为止，双膦酸盐和地诺单抗都被认为是AIs患者骨质疏松性骨折一级预防的一线药物。它们已被证明在增加骨密度和减少骨折发生率方面有效，但它们也被证明可以提高无病生存率(DFS)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Bone modifying agents in postmenopausal breast cancer patients treated with aromatase inhibitors: beyond bone protection?

Estrogen-receptor positive tumours represent the majority of breast cancers in postmenopausal women. Adjuvant endocrine therapy with aromatase inhibitors (AIs), continued for up to 10 years in high-risk patients, reduces by 40% the risk of recurrence. However, this therapy, among other side effects, is burdened with a higher incidence of osteoporotic bone fractures. To date, both bisphosphonates and denosumab are recognized as first-line drugs in the primary prevention of osteoporotic fractures in patients treated with AIs. They have demonstrated their effectiveness in increasing bone mineral density and in reducing the incidence of fractures, but they have also been shown to improve disease free survival (DFS).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.